145 results on '"Telliez, Jean-Baptiste"'
Search Results
2. The advantages of describing covalent inhibitor in vitro potencies by IC50 at a fixed time point. IC50 determination of covalent inhibitors provides meaningful data to medicinal chemistry for SAR optimization
3. Inhibition of T-cell activity in alopecia areata: recent developments and new directions
4. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments
5. Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open‐Label, Phase 1 Study
6. Janus Kinase Inhibitors
7. Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open‐Label, Phase 1 Study.
8. Parsing the Interferon Transcriptional Network and Its Disease Associations
9. Network pharmacology of JAK inhibitors
10. Editorial: JAK inhibition in autoimmune and inflammatory diseases
11. The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans
12. Janus Kinase Inhibitors
13. Pharmacologic Inhibition of Tpl2 Blocks Inflammatory Responses in Primary Human Monocytes, Synoviocytes, and Blood
14. Identification of a novel class of selective Tpl2 kinase inhibitors: 4-Alkylamino-[1,7]naphthyridine-3-carbonitriles
15. Catalytically Active MAP KAP Kinase 2 Structures in Complex with Staurosporine and ADP Reveal Differences with the Autoinhibited Enzyme
16. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition
17. PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor
18. Hippocampus-dependent learning and memory is impaired in mice lacking the Ras-guanine-nucleotide releasing factor 1 (Ras-GRF1)
19. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments.
20. Mutational analysis and NMR studies of the death domain of the tumor necrosis factor receptor-1
21. Solution Structure of N-TRADD and Characterization of the Interaction of N-TRADD and C-TRAF2, a Key Step in the TNFR1 Signaling Pathway
22. LRDD, a novel leucine rich repeat and death domain containing protein
23. Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors
24. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)
25. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
26. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases
27. Engagement of Tumor Necrosis Factor (TNF) Receptor 1 Leads to ATF-2- and p38 Mitogen-activated Protein Kinase-dependent TNF-α Gene Expression
28. Parsing the Interferon Transcriptional Network and Its Disease Associations
29. Microfluidic-Enabled Intracellular Delivery of Membrane Impermeable Inhibitors to Study Target Engagement in Human Primary Cells
30. An Updated Analysis of In vitro Cytokine Inhibition Profiles of a Number of Janus Kinase Inhibitors at Clinically Meaningful Concentrations
31. Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
32. rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
33. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments
34. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases
35. Microfluidic-Enabled Intracellular Delivery of Membrane Impermeable Inhibitors to Study Target Engagement in Human Primary Cells
36. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition
37. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines
38. Discovery of indazoles as inhibitors of Tpl2 kinase
39. Identification and SAR of a new series of thieno[3,2- d]pyrimidines as Tpl2 kinase inhibitors
40. Meroterpenoid MAPKAP (MK2) Inhibitors Isolated from the Indonesian Marine Sponge Acanthodendrilla sp
41. ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling
42. Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
43. Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-α production in human whole blood
44. Inhibitors of Tumor Progression Loci-2 (Tpl2) Kinase and Tumor Necrosis Factor α (TNF-α) Production: Selectivity and in Vivo Antiinflammatory Activity of Novel 8-Substituted-4-anilino-6-aminoquinoline-3-carbonitriles
45. Inhibition of Tpl2 kinase and TNFα production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritis
46. MAPKAP Kinase 2-Deficient Mice Are Resistant to Collagen-Induced Arthritis
47. Inhibition of Tpl2 kinase and TNF-α production with 1,7-naphthyridine-3-carbonitriles: Synthesis and structure–activity relationships
48. Phaeochromycins A−E, Anti-inflammatory Polyketides Isolated from the Soil Actinomycete Streptomyces phaeochromogenes LL-P018
49. Meroterpenoid MAPKAP (MK2) Inhibitors Isolated from the Indonesian Marine Sponge Acanthodendrilla sp.
50. Distinct Cellular Functions of MK2
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.